Barekat Pharmaceutical Group, established in 2010 (1389 AH), operates with over 25 subsidiary companies under its umbrella. Initially founded as Tadbir Advanced Pharmaceutical Technologies Company, the group was created based on in-depth analysis and strategic planning for the future of Iran’s pharmaceutical industry. The primary aim of the group is to meet the growing healthcare needs of society.
As a knowledge-based economic entity, Barekat health and Pharmaceutical Group has strategically focused on health products, with the overarching goal of contributing to the realization of Iran’s Vision 2025 and aligning with the National Comprehensive Scientific Plan.
Our operations are grounded in fulfilling our social responsibilities, prioritizing human values, and promoting the public good. One of the group’s core objectives is to promote social justice by improving access to innovative health products, particularly for underprivileged communities. This is achieved by producing medications at lower costs, making healthcare more affordable and accessible.
Barekat health and Pharmaceutical Group’s extensive strategy includes venturing into cutting-edge pharmaceutical fields such as biotechnology, advanced drug delivery systems like nanotechnology, slow-release drugs, and emerging health technologies. Additionally, the group aims to spearhead the development of cellular and molecular industries, including cell therapy, gene therapy, immunotherapy, and tissue engineering technologies.